ALEXANDRIA, Va., May 26 -- United States Patent no. 12,637,718, issued on May 26, was assigned to Cardiff Oncology Inc. (San Diego).
"Predictive biomarkers for onvansertib treatment" was invented by Peter J.P. Croucher (San Diego), Maya Ridinger (San Diego) and Mark Erlander (San Diego).
According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein include methods, compositions, and kits suitable for use in treating a hematological cancer in a subject. In some embodiments, the method comprises determining the presence or absence of at least one mutation in one or more genes encoding a spliceosome protein in sample nucleic acids from the subject; and administering onvansertib and decitabine to the subject, if...